PMID- 34318734
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220716
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Print)
IS  - 0269-8811 (Linking)
VI  - 36
IP  - 6
DP  - 2022 Jun
TI  - Prospects for new drugs to treat binge-eating disorder: Insights from 
      psychopathology and neuropharmacology.
PG  - 680-703
LID - 10.1177/02698811211032475 [doi]
AB  - BACKGROUND: Binge-eating disorder (BED) is a common psychiatric condition with 
      adverse psychological and metabolic consequences. Lisdexamfetamine (LDX) is the 
      only approved BED drug treatment. New drugs to treat BED are urgently needed. 
      METHODS: A comprehensive review of published psychopathological, pharmacological 
      and clinical findings. RESULTS: The evidence supports the hypothesis that BED is 
      an impulse control disorder with similarities to ADHD, including responsiveness 
      to catecholaminergic drugs, for example LDX and dasotraline. The target product 
      profile (TPP) of the ideal BED drug combines treating the psychopathological 
      drivers of the disorder with an independent weight-loss effect. Drugs with proven 
      efficacy in BED have a common pharmacology; they potentiate central noradrenergic 
      and dopaminergic neurotransmission. Because of the overlap between 
      pharmacotherapy in attention deficit hyperactivity disorder (ADHD) and BED, 
      drug-candidates from diverse pharmacological classes, which have already failed 
      in ADHD would also be predicted to fail if tested in BED. The failure in BED 
      trials of drugs with diverse pharmacological mechanisms indicates many possible 
      avenues for drug discovery can probably be discounted. CONCLUSIONS: (1) The 
      efficacy of drugs for BED is dependent on reducing its core psychopathologies of 
      impulsivity, compulsivity and perseveration and by increasing cognitive control 
      of eating. (2) The analysis revealed a large number of pharmacological mechanisms 
      are unlikely to be productive in the search for effective new BED drugs. (3) The 
      most promising areas for new treatments for BED are drugs, which augment 
      noradrenergic and dopaminergic neurotransmission and/or those which are effective 
      in ADHD.
FAU - Heal, David J
AU  - Heal DJ
AUID- ORCID: 0000-0002-6128-9632
AD  - DevelRx Ltd, Nottingham, UK.
FAU - Smith, Sharon L
AU  - Smith SL
AD  - DevelRx Ltd, Nottingham, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210728
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - SJT761GEGS (Lisdexamfetamine Dimesylate)
SB  - IM
MH  - *Attention Deficit Disorder with Hyperactivity/drug therapy
MH  - *Binge-Eating Disorder/drug therapy
MH  - Humans
MH  - Lisdexamfetamine Dimesylate/therapeutic use
MH  - Neuropharmacology
MH  - Weight Loss
PMC - PMC9150143
OTO - NOTNLM
OT  - Binge-eating disorder
OT  - animal models
OT  - attention deficit hyperactivity disorder
OT  - binge eating
OT  - drugs
OT  - obesity
COIS- Declaration of conflicting interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: David J Heal and Sharon L Smith are shareholders and 
      employees of DevelRx Ltd. DevelRx provides consultancy support to the 
      pharmaceutical industry.
EDAT- 2021/07/29 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/05/30
CRDT- 2021/07/28 08:43
PHST- 2021/07/29 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2021/07/28 08:43 [entrez]
PHST- 2022/05/30 00:00 [pmc-release]
AID - 10.1177_02698811211032475 [pii]
AID - 10.1177/02698811211032475 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2022 Jun;36(6):680-703. doi: 10.1177/02698811211032475. Epub 
      2021 Jul 28.